Baron Financials ETF on Axsome Therapeutics
Thesis
Baird added Axsome Therapeutics as one of several commercial-stage therapeutic companies with promising growth potential. The company already has multiple marketed products. Baird identifies the recently approved therapy Auvelity as the most exciting growth opportunity, particularly for treating agitation associated with dementia and Alzheimer's disease.
“the most exciting growth opportunity is its recently approved therapy Auvelity”